May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Vitreous Levels of Angiopoietin 1 and 2 in Diabetic Patients
Author Affiliations & Notes
  • J.I. Patel
    Vitreo & Med Retina, Moorfields Eye Hospital, London, United Kingdom
  • P.G. Hykin
    Med Retina, Moorfields Eye Hospital, London, United Kingdom
  • M. Boulton
    Department of Optometry and Vision Sciences, Cardiff University, Cardiff, United Kingdom
  • Z. Gregor
    Department of Optometry and Vision Sciences, Cardiff University, Cardiff, United Kingdom
  • I.A. Cree
    Pathology, Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships  J.I. Patel, Regeneron F; P.G. Hykin, None; M. Boulton, None; Z. Gregor, None; I.A. Cree, Regeneron F.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 2250. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J.I. Patel, P.G. Hykin, M. Boulton, Z. Gregor, I.A. Cree; Vitreous Levels of Angiopoietin 1 and 2 in Diabetic Patients . Invest. Ophthalmol. Vis. Sci. 2003;44(13):2250.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: The angiopoietins 1 and 2 are growth factors that interact with vascular endothelial growth factor (VEGF) to promote angiogenesis in animal and in vitro models. However there is little information regarding the levels of the angiopoietins in the vitreous of patients with diabetic retinopathy even though levels for VEGF are known. This study aims to determine these levels. Methods: The vitreous of 17 patients with nonproliferative diabetic retinopathy (NPDR) and clinically significant diabetic macular edema (CSME), 10 patients with proliferative diabetic retinopathy and 5 patients with macular hole obtained at pars plana vitrectomy were analysed for the angiopoietins using chemiluminescent immunoassay. The level of sensitivity for the angiopoietin 1 assay was 5 pg/ml; for the angiopoietin 2 assay 1 ng/ml. Results: In NPDR with CSME the median angiopoietin 1 level was 2002 pg/ml (range 289-5820 pg/ml); for angiopoietin 2 a median of 4000 pg/ml (range 1341-14329 pg/ml). The median level in PDR for angiopoietin 1 was 186 pg/ml (range 26-2292 pg/ml); for angiopoietin 2 levels were less than sensitivity of the assay. For macular hole patients angiopoietin 1 levels were low (median 17 pg/ml) whilst the angiopoietin 2 levels were below assay sensitivity. Conclusions: Angiopoietin 2 vitreous levels were twice that of angiopoietin 1 in NPDR with CSME patients. Angiopoietin 2 is the natural antagonist of angiopoietin 1 which is thought to act as a anti-permeability agent. The predominance of Angiopoietin 2 may be permissive for VEGF induced retinal vascular permeability in patients with CSME. The relative low levels of both Angiopoietin 1 and 2 in patients with proliferative diabetic retinopathy may reflect the established nature of the neovascularization in such cases proceeding to vitrectomy surgery.

Keywords: diabetic retinopathy • retinal neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×